Brief: Annexin Publishes Positive Results In Co's Phase 1-Study
Sept 14 (Reuters) - Annexin Pharmaceuticals AB (publ)
ANNX.ST :
* POSITIVE RESULTS IN CO'S PHASE 1-STUDY
* DRUG CANDIDATE ANXV WAS WELL TOLERATED
Source text for Eikon: ID:nWkr3mhlws
Further company coverage: ANNX.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln
Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
Brief: Annexin Pharmaceuticals Gets International Nonproprietary Name Drug Candidate Anxv
Brief: Annexin Pharmaceuticals Updates On Nine Patients Treated In Nexus Study
Brief: Annexin's Rights Issue 98% Subscribed